drugset
drugset / Trial / NCT04624711

Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer

NCT04624711 ↗

Phase 2 Unknown 40 enrolled The First Affiliated Hospital with Nanjing Medical University
NaSingle-groupOpen-labelTreatment

Summary

This is a multicenter, phase II, open-label, single-arm investigator initiated trial to evaluate the efficacy and safety of eribulin mesylate combined with anlotinib in metastatic HER2 negative breast cancer patients.

Timeline

Start
2021-03-01
Primary completion
2022-06
Completion
2022-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Catequentinib Small molecule 12 mg Oral
Subject Eribulin Small molecule 1.4 mg/m2 —

Indications

Her2-receptor negative breast cancer